Lymecycline

Summary

Lymecycline (CHEMBL2103929) is an approved small-molecule protein synthesis inhibitor (ATC J01AA04); indicated across 2 conditions including bacterial infectious disease and acne.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01AA04
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 602.6 Da · C29H38N4O10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2103929
Name	Lymecycline
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	54707177
ChEBI	CHEBI:59040
ATC	J01AA04
Molecular formula	C29H38N4O10
Molecular weight	602.6
InChIKey	PZTCVADFMACKLU-UEPZRUIBSA-N

SMILES: C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)NCNCCCC[C@@H](C(=O)O)N)N(C)C)O

IUPAC name: (2S)-6-[[[(4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carbonyl]amino]methylamino]-2-aminohexanoic acid

ChEBI definition: A tetracycline-based broad-spectrum antibiotic. It is approximately 5000 times more soluble than tetracycline base and is unique amongst tetracyclines in that it is absorbed by the “active transport” process across the intestinal wall.

Pharmacological roles (ChEBI): protein synthesis inhibitor, antiprotozoal drug, antibacterial drug, antimicrobial agent.

Also known as: Ciclolysal, Ciclolysine, Limeciclina, Lymecycline, Mucomycin, Tetracycline-l-methylenelysine, Tetracyclinemethylenelysine, Tetralysal, Tetralysal 150, Tetralysal 300, LYMECYCLINE, lymecycline

Patent coverage: 1,446 distinct patent families (5,572 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Estrogen receptor, Prostaglandin G/H synthase 2, Androgen receptor, Nuclear receptor subfamily 1 group I member 2, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q63921	6.55	AC50	281	nM	CHEMBL_ACT_25173973
PTGS2	5.92	AC50	1200	nM	CHEMBL_ACT_25165775
NR1I2	5.41	AC50	3900	nM	CHEMBL_ACT_25187886

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
acne	3	MONDO:0011438	EFO:0003894

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01661985	PHASE4	UNKNOWN	Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Treatment Commenced

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).